| 2020 | | A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis | 서창희 |
| 2020 | | A pharmacokinetic evaluation of the rituximab biosimilar CT-P10 in the treatment of rheumatoid arthritis | 서창희 |
| 2021 | | Biologic therapy for amyloid A amyloidosis secondary to rheumatoid arthritis treated with interleukin 6 therapy: Case report and review of literature | 김영배, 김지원, 김현아, 서창희, 정주양 |
| 2023 | | Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview | 서창희 |
| 2017 | | Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab | 김현아, 서창희 |
| 2022 | | Clinical Features and Drug Retention of TNF Inhibitors in Older Patients with Ankylosing Spondylitis: Results from the KOBIO Registry | 김지원, 김현아, 서창희, 정주양 |
| 2018 | | Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial | 서창희 |
| 2017 | | Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares | 김현아, 서창희 |
| 2012 | | Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy | 김현아, 서창희 |
| 2019 | | Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study | 김현아 |
| 2023 | | Efficacy and drug retention of tofacitinib in rheumatoid arthritis: from the nationwide Korean College of Rheumatology Biologics registry | 김지원, 김현아, 서창희, 정주양 |
| 2024 | | Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo-controlled trial in North East Asia | 서창희 |
| 2019 | | Efficacy and safety of mycophenolate mofetil and tacrolimus combination therapy in patients with lupus nephritis: a nationwide multicentre study | 서창희 |
| 2014 | | Efficacy and safety of PG201 (Layla(®)) and celecoxib in the treatment of symptomatic knee osteoarthritis: a double-blinded, randomized, multi-center, active drug comparative, parallel-group, non-inferiority, phase III study. | 서창희 |
| 2020 | | Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies | 서창희 |
| 2017 | | Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis | 서창희 |
| 2019 | | Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial | 서창희 |
| 2016 | | Efficacy of tocilizumab therapy in Korean patients with adult-onset Still's disease: a multicentre retrospective study of 22 cases | 김현아 |
| 2017 | | Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial | 서창희 |
| 2018 | | Factors associated with quality of life and functional disability among rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs for at least 6 months | 서창희 |
| 2020 | | Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis | 서창희 |
| 2019 | | Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study | 서창희 |
| 2016 | | Mesenteric vasculitis after G-CSF administration in a severe neutropenic patient with systemic lupus erythematosus | 김현아, 서창희, 정주양 |
| 2012 | | Nonsteroidal antiinflammatory drugs (NSAID) versus NSAID with hydroxychloroquine in treatment of chemotherapy-related arthropathy: open-label multicenter pilot study | 김현아, 서창희 |
| 2018 | | Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil | 김현아, 서창희 |
| 2004 | | Pure red cell aplasia and adult-onset Still's disease. | 박해심, 서창희, 조성란 |
| 2020 | | Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score-Matched Analysis from the Korean College of Rheumatology Biologics Registry | 김현아 |
| 2020 | | Retention rate and long-term safety of biosimilar CT-P13 in patients with ankylosing spondylitis: data from the Korean College of Rheumatology Biologics registry | 김현아 |
| 2020 | | Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry | 김현아 |
| 2015 | | Rheumatoid arthritis patients fulfilling Korean National Health Insurance reimbursement guidelines for anti-tumor necrosis factor-α treatment and comparison to other guidelines. | 서창희 |
| 2013 | | Serum growth arrest-specific protein 6 levels are a reliable biomarker of disease activity in systemic lupus erythematosus. | 김현아, 서창희, 전자영, 정주양 |
| 2020 | | Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activity | 서창희 |
| 2017 | | Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry | 김현아 |
| 2012 | | Therapeutic responses and prognosis in adult-onset Still's disease | 김현아, 서창희 |
| 2018 | | Treat-to-Target Strategy for Asian Patients with Early Rheumatoid Arthritis: Result of a Multicenter Trial in Korea | 서창희 |
| 2022 | | Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis | 서창희 |
